Cassava shares sink on plans to stop Alzheimer's drug studies
6 days ago · Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, sending shares of the drug developer plummeting 83% in early trading on Monday.
Cassava Sciences and its Alzheimer's drug are done. The damage …
6 days ago · The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, failing a clinical trial.
PRESS RELEASES - Cassava Sciences, Inc.
Sep 24, 2024 · AUSTIN, Texas , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, August 8 th …
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary …
6 days ago · AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, today announced that the topline results from the Phase 3 ReThink-ALZ study of ...
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary …
6 days ago · Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease.
Cassava Sciences: Probably The End Of The Saga - Seeking Alpha
4 days ago · Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation of all ongoing trials. ... transparency and material news on the ...
Cassava Sciences’ stock craters after Alzheimer’s disease trial fails ...
6 days ago · News is the latest setback for the clinical-stage biotech, which was the subject of SEC and Justice Department investigations earlier this year ... Cassava Sciences Inc.’s stock tumbled 85% ...
After Cassava Alzheimer drug fiasco, FDA must protect patients
Oct 2, 2024 · For nearly a year, my stance on Cassava Sciences and its Alzheimer’s disease drug candidate simufilam has been clear: Emerging evidence shows the drug is inert, and patients with Alzheimer’s...
Cassava Sciences Resolves SEC Investigation
Sep 26, 2024 · Cassava, without admitting or denying the SEC’s allegations, agreed to pay a monetary penalty of $40 million. The Company cooperated fully with the SEC’s investigation and has implemented remedial measures.
Cassava Sciences: Phase 3 Alzheimer's Drug Fail The Final Nail In …
5 days ago · Cassava Sciences' Alzheimer's drug simufilam failed key trial endpoints, leading to a stock plunge. ... Predictably, Cassava stock sank from $26.5 per share, to $4 per share on yesterday's news ...